The regulatory landscape for research peptides has undergone significant changes in 2026, driven by the FDA’s review of peptide compounding under Section 503A. This article explains the Category 2 reclassification, its implications, and what researchers and peptide raw material suppliers need to know.
What Is the 503A Bulks List?
Section 503A of the Federal Food, Drug, and Cosmetic Act regulates pharmacy compounding of drug products. The 503A Bulks List identifies bulk drug substances that may be used in compounding. Substances on the list are legally eligible for compounding, as are substances designated as “under evaluation” under Category 1.
The Category 2 Designation
Category 2 substances are those that pose a “significant safety risk” and cannot be legally compounded under Section 503A. In April 2026, the FDA announced a plan to reclassify more than a dozen peptides from Category 2 back to Category 1.
Twelve Peptides Removed from Category 2
The FDA has now removed twelve peptides from the Category 2 list, taking them out of the “significant safety risk” designation. However, with the exception of GHK-Cu, none of these peptides have been recategorized to Category 1. They currently exist in a regulatory gray zone— no longer designated as posing a significant safety risk, but not yet affirmatively authorized for compounding.
The July 2026 PCAC Meeting
On July 23-24, 2026, the Pharmacy Compounding Advisory Committee (PCAC) convened to evaluate seven bulk peptide drug substances: BPC-157, KPV, TB-500, MOTS-c, Emideltide (DSIP), Semax, and Epitalon. FDA career staff recommended against inclusion for all seven. Despite this, the PCAC voted in favor of adding six peptides—BPC-157, TB-500, MOTS-c, epitalon, and semax—to the 503A Bulks List.
The Regulatory Road Ahead
The PCAC votes themselves did not amend the 503A Bulks List. The FDA’s next step is formal notice-and-comment rulemaking to either include or exclude the recommended peptides—a process that could extend well into 2027 or 2028.
Implications for Researchers
While these regulatory changes primarily affect compounding pharmacies, they have indirect implications for researchers:
– Supply Chain Transparency : Increased scrutiny may improve overall quality standards.
– Documentation : Researchers should expect more rigorous documentation from peptide raw material suppliers.
– Legality : Research-use-only peptides remain available for laboratory studies.
Product Disclaimer & Terms of Use
IMPORTANT NOTICE: FOR RESEARCH USE ONLY (RUO)
This product is intended exclusively for laboratory research and scientific development purposes. It is NOT a drug, food, medical device, cosmetic, or diagnostic product.